My NCBI | Sign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 380

    1.

    Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats.

    Pospisilik JA, Stafford SG, Demuth HU, Brownsey R, Parkhouse W, Finegood DT, McIntosh CH, Pederson RA.

    Diabetes. 2002 Apr;51(4):943-50.PMID: 11916911 [PubMed - indexed for MEDLINE]Related articlesFree article

    2.

    Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study.

    Pospisilik JA, Stafford SG, Demuth HU, McIntosh CH, Pederson RA.

    Diabetes. 2002 Sep;51(9):2677-83.PMID: 12196458 [PubMed - indexed for MEDLINE]Related articlesFree article

    3.

    Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

    Pospisilik JA, Martin J, Doty T, Ehses JA, Pamir N, Lynn FC, Piteau S, Demuth HU, McIntosh CH, Pederson RA.

    Diabetes. 2003 Mar;52(3):741-50.PMID: 12606516 [PubMed - indexed for MEDLINE]Related articlesFree article

    4.

    Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.

    Wargent E, Stocker C, Augstein P, Heinke P, Meyer A, Hoffmann T, Subramanian A, Sennitt MV, Demuth HU, Arch JR, Cawthorne MA.

    Diabetes Obes Metab. 2005 Mar;7(2):170-81.PMID: 15715890 [PubMed - indexed for MEDLINE]Related articles

    5.

    Efficacy of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide (P32/98) in fatty Zucker rats with incipient and manifest impaired glucose tolerance.

    Augstein P, Berg S, Heinke P, Altmann S, Salzsieder E, Demuth HU, Freyse EJ.

    Diabetes Obes Metab. 2008 Sep;10(10):850-61. Epub 2007 Oct 29.PMID: 17970756 [PubMed - indexed for MEDLINE]Related articles

    6.

    Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice.

    Liu X, Harada N, Yamane S, Kitajima L, Uchida S, Hamasaki A, Mukai E, Toyoda K, Yamada C, Yamada Y, Seino Y, Inagaki N.

    Life Sci. 2009 Jun 19;84(25-26):876-81. Epub 2009 Apr 7.PMID: 19358859 [PubMed - indexed for MEDLINE]Related articles

    7.

    Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide.

    Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU.

    Diabetes. 1998 Aug;47(8):1253-8.PMID: 9703325 [PubMed - indexed for MEDLINE]Related articlesFree article

    8.

    Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats.

    Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X.

    Diabetologia. 1999 Nov;42(11):1324-31.PMID: 10550416 [PubMed - indexed for MEDLINE]Related articles

    9.

    Defective glucose-dependent insulinotropic polypeptide receptor expression in diabetic fatty Zucker rats.

    Lynn FC, Pamir N, Ng EH, McIntosh CH, Kieffer TJ, Pederson RA.

    Diabetes. 2001 May;50(5):1004-11.PMID: 11334402 [PubMed - indexed for MEDLINE]Related articlesFree article

    10.

    Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.

    Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I.

    J Pharmacol Exp Ther. 2004 Aug;310(2):614-9. Epub 2004 Mar 23.PMID: 15039452 [PubMed - indexed for MEDLINE]Related articlesFree article

    11.

    Altered glucose dependence of glucagon-like peptide I(7-36)-induced insulin secretion from the Zucker (fa/fa) rat pancreas.

    Jia X, Elliott R, Kwok YN, Pederson RA, McIntosh CH.

    Diabetes. 1995 May;44(5):495-500.PMID: 7729605 [PubMed - indexed for MEDLINE]Related articles

    12.

    NN414, a SUR1/Kir6.2-selective potassium channel opener, reduces blood glucose and improves glucose tolerance in the VDF Zucker rat.

    Carr RD, Brand CL, Bodvarsdottir TB, Hansen JB, Sturis J.

    Diabetes. 2003 Oct;52(10):2513-8.PMID: 14514634 [PubMed - indexed for MEDLINE]Related articlesFree article

    13.

    Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats.

    Sudre B, Broqua P, White RB, Ashworth D, Evans DM, Haigh R, Junien JL, Aubert ML.

    Diabetes. 2002 May;51(5):1461-9.PMID: 11978643 [PubMed - indexed for MEDLINE]Related articlesFree article

    14.

    Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice.

    Reimer MK, Holst JJ, Ahrén B.

    Eur J Endocrinol. 2002 May;146(5):717-27.PMID: 11980629 [PubMed - indexed for MEDLINE]Related articlesFree article

    15.

    Improved glucose tolerance in rats treated with the dipeptidyl peptidase IV (CD26) inhibitor Ile-thiazolidide.

    Pauly RP, Demuth HU, Rosche F, Schmidt J, White HA, Lynn F, McIntosh CH, Pederson RA.

    Metabolism. 1999 Mar;48(3):385-9.PMID: 10094118 [PubMed - indexed for MEDLINE]Related articles

    16.

    Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats.

    Hinke SA, Gelling RW, Pederson RA, Manhart S, Nian C, Demuth HU, McIntosh CH.

    Diabetes. 2002 Mar;51(3):652-61.PMID: 11872663 [PubMed - indexed for MEDLINE]Related articlesFree article

    17.

    Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

    Ahrén B, Holst JJ, Mårtensson H, Balkan B.

    Eur J Pharmacol. 2000 Sep 15;404(1-2):239-45.PMID: 10980284 [PubMed - indexed for MEDLINE]Related articles

    18.

    Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo.

    Someya Y, Tahara A, Nakano R, Matsuyama-Yokono A, Nagase I, Fukunaga Y, Takasu T, Hayakawa M, Shibasaki M.

    Naunyn Schmiedebergs Arch Pharmacol. 2008 May;377(3):209-17. Epub 2008 Apr 9.PMID: 18398600 [PubMed - indexed for MEDLINE]Related articles

    19.

    Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year.

    Ahrén B, Pacini G, Foley JE, Schweizer A.

    Diabetes Care. 2005 Aug;28(8):1936-40.PMID: 16043735 [PubMed - indexed for MEDLINE]Related articlesFree article

    20.

    7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.

    Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, Saeki T, Tanaka I.

    J Pharmacol Exp Ther. 2006 Dec;319(3):1253-7. Epub 2006 Sep 15.PMID: 16980568 [PubMed - indexed for MEDLINE]Related articlesFree article

    Supplemental Content

    Filter your results:

    Find related data

    Recent activity